Wegovy is available in the UK through two routes in 2026: NHS (free or £9.90 per prescription in England, but requires BMI ≥35 with a comorbidity and a Tier 3 specialist referral with 6-18+ month waits) or privately through GPhC-regulated online pharmacies (£89.99-£315/month depending on dose, annual spend £2,400-£3,600). Start by checking your BMI eligibility and booking a GP appointment.
Wegovy has been through a rough introduction to the UK. After its 2023 launch, supply shortages dominated 2024 and most of 2025 — people were prescribed it and simply couldn’t get hold of it. By 2026, that’s largely resolved. Stock is stable across most UK pharmacies, both NHS and private. But the landscape has also got more complicated. There are two genuinely different pathways to access it, each with real trade-offs in cost, waiting time, and eligibility. This piece covers both honestly. No marketing, no panic — just the practical picture for UK adults weighing up whether Wegovy is worth pursuing, and if so, how to actually get it.
What Wegovy actually is — and how it’s different from Ozempic
You’ll have seen the name Ozempic everywhere since 2023. Wegovy is made by the same manufacturer, Novo Nordisk, and uses the same active ingredient: semaglutide. But they’re not interchangeable products.
Ozempic is licensed in the UK for type 2 diabetes management. Wegovy is licensed specifically for weight management. The key difference is the dosing. Ozempic tops out at 1mg semaglutide per week. Wegovy goes up to 2.4mg per week — more than double — which is the dose that produced the most significant weight loss in clinical trials.
Both are once-weekly subcutaneous injections using a pre-filled pen. You inject into the abdomen, thigh, or upper arm. It’s not a tablet, and it’s not something you take daily.
The drug belongs to a class called GLP-1 receptor agonists. In plain terms, it mimics a gut hormone that tells your brain you’re full, and it slows down how quickly food leaves your stomach. You feel less hungry, you eat less, and over time you lose weight.
The STEP clinical trial programme — the large-scale studies that led to Wegovy’s approval — showed an average 15% reduction in body weight over 68 weeks. That’s not a trivial number. But it’s an average, and individual results vary considerably.
Wegovy has been authorised for weight management in the UK by the MHRA and is recommended by NICE under technology appraisal TA875, which set out the specific NHS eligibility criteria.
NHS eligibility — the NICE TA875 criteria in plain English
Getting Wegovy on the NHS isn’t simply a matter of asking your GP. NICE TA875 lays out specific criteria, and they’re fairly restrictive.
You need a BMI of 35 kg/m² or above, plus at least one weight-related comorbidity. The qualifying conditions are: type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglycerides), obstructive sleep apnoea, or cardiovascular disease. Without a comorbidity, a BMI of 35 alone isn’t enough.
There is an exceptional pathway for people with a BMI of 30 or above, but only if you meet criteria for specialist weight management — essentially, if your clinical situation is serious enough that a specialist team decides you need Tier 3 intervention.
NICE also built in an important equity adjustment. If you’re of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean heritage, your BMI thresholds are reduced by 2.5 kg/m². That means you’d qualify at a BMI of 32.5 rather than 35, or 27.5 rather than 30 on the exceptional pathway. This reflects the well-established evidence that these populations face higher metabolic risks at lower BMI levels.
Here’s the bit that catches people out: your GP cannot prescribe Wegovy directly. It must be prescribed within an NHS specialist weight management service — a Tier 3 or Tier 4 service. Your GP can refer you, but the prescription itself comes from the specialist team.
Treatment is limited to a maximum of two years on the NHS. At the six-month mark, there’s a mandatory review. You need to have lost at least 5% of your starting body weight to continue. If you haven’t hit that threshold, the treatment is stopped.
A significant development came in April 2026, when NHS England expanded access to cover over one million adults at elevated risk of heart attack or stroke — not just those seeking weight loss, but people with established cardiovascular disease who could benefit from semaglutide’s cardioprotective effects.
NHS access reality — the waiting list picture
Meeting the eligibility criteria is one thing. Actually getting an appointment is another.
Wegovy is only available through Tier 3 specialist weight management services, and those services have long waiting lists. Depending on where you live in England, you could wait anywhere from six months to 18 months or more for your initial Tier 3 assessment. In some areas, the wait is even longer.
This isn’t uniform across the country. England’s healthcare system is managed regionally by Integrated Care Boards (ICBs), and each ICB makes its own commissioning decisions. Some ICBs have invested more heavily in expanding weight management capacity. Others haven’t. The result is a postcode lottery that’s difficult to sugar-coat.
The April 2026 NHS England expansion — covering adults at high cardiovascular risk — is a meaningful shift. It potentially opens Wegovy access to over a million additional people. But capacity to deliver that expansion is still catching up with policy intent.
What should you actually do? Book a GP appointment and ask specifically for a referral to your local Tier 3 weight management service. Don’t assume your GP will bring it up unprompted. Be direct: you’d like to discuss whether you meet the NICE TA875 criteria and whether a specialist referral is appropriate. If your GP agrees, get the referral submitted and ask for an estimated waiting time for your area.
Private route — what it costs in 2026 and where
If the NHS waiting list feels unworkable — or you don’t quite meet the NICE criteria — private prescription is the alternative.
Private Wegovy in the UK is available through online pharmacies and some high-street chains. The model is broadly similar across providers: you complete a medical questionnaire, a UK-registered clinician reviews your answers (sometimes with a phone or video consultation), and if approved, a prescription is issued and the medication is delivered to your door.
Private eligibility is typically less restrictive than the NHS route. Most providers require a BMI of 30 or above, or a BMI of 27 with at least one weight-related comorbidity. You don’t need a specialist referral.
Pricing varies meaningfully by provider and by dose. Here’s what the 2026 UK market looks like:
Over a full year of treatment, expect to spend between £2,400 and £3,600 privately. That’s a significant ongoing cost, and it’s worth being realistic about it before you start.
What you’ll pay at each dose
The dose escalation schedule matters for your wallet. You don’t start at the full 2.4mg — you build up over 16 weeks, and prices increase with each step.
At the 0.25mg starter dose, you’re looking at roughly £90 to £120 per month depending on provider. The 0.5mg step typically costs £98 to £150. At 1mg, expect £108 to £180. The 1.7mg pen — the penultimate step — ranges from £162 to £230. The 2.4mg maintenance dose, which you’ll stay on long-term, runs from £186 to £315 per month.
The full 16-week titration period — covering all four dose increases — will cost a minimum of £500 to £700 at the cheapest end of the market. After that, you’re locked into maintenance pricing of roughly £186 to £299 per month for as long as you continue treatment.
Worth knowing: some providers charge separately for the initial consultation, though many include it. Delivery fees are sometimes extra, sometimes bundled. Always check the total monthly cost before committing.
Common side effects — what to expect in the first 8 weeks
Most people experience some side effects when starting Wegovy, and they’re most pronounced during the first four to eight weeks, particularly during dose increases.
Nausea is the most commonly reported effect. It can range from mild queasiness to something more persistent. Vomiting occurs in some people, though it’s less frequent than nausea alone. Bowel habits often shift — you might get diarrhoea or constipation, sometimes alternating between the two.
Fatigue and headaches are reported reasonably often in the early weeks. Heartburn and acid reflux can crop up too, particularly after meals. Some people notice mild reactions at the injection site — redness, itching, or a small lump.
Most of these effects are manageable and tend to settle as your body adjusts to the medication. Practical tactics that help: eat smaller, more frequent meals; avoid particularly fatty or rich foods, especially around dose increases; don’t rush the titration schedule — your clinician can slow it down if side effects are rough; and stay well hydrated.
If side effects are severe or aren’t improving after several weeks, talk to your prescriber. There’s no prize for suffering through it silently.
Serious side effects and who shouldn’t take it
⚠️ Serious flags — who should not take Wegovy
Pancreatitis — inflammation of the pancreas — is rare but serious. The hallmark symptom is severe, persistent abdominal pain that often radiates to the back. If this happens, seek urgent medical attention.
Gallbladder problems, including gallstones, have been reported with GLP-1 receptor agonists. Symptoms include sharp pain in the upper right abdomen, fever, or jaundice.
Thyroid cancer warning: There is a black box warning in the US, and the UK’s MHRA flags personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) as a contraindication. If either runs in your family, Wegovy is not for you.
Pregnancy: If you’re pregnant or planning pregnancy, you must stop Wegovy at least two months before trying to conceive. It’s not authorised for use during pregnancy.
Diabetes interaction: For people with type 2 diabetes taking insulin or sulphonylureas, there’s an increased risk of hypoglycaemia when adding semaglutide. Your diabetes team would need to manage this carefully.
Seek urgent help if you experience: severe or persistent abdominal pain, persistent vomiting that won’t settle, a new unexplained rash, or signs of jaundice.
UK buying safety — the MHRA warning and how to avoid counterfeit Wegovy
This section matters. In 2024 and 2025, the MHRA issued alerts about counterfeit Wegovy pens being sold through illegal online channels. Fake semaglutide has been found in pens that look identical to the real product but contain unknown — sometimes dangerous — substances.
The rules are straightforward. In the UK, Wegovy is prescription-only. It is never available over the counter, and any site offering it without a prescription is operating illegally. Only buy through a GPhC-regulated pharmacy. You can verify any pharmacy’s registration at gphc.org.uk.
Red flags to watch for: no prescription or medical questionnaire required, dramatic “save 80%” offers that undercut every legitimate provider, sellers operating through Telegram, WhatsApp, or social media DMs, and Eastern European-registered sellers actively marketing to UK consumers.
Proper storage matters too. Wegovy pens must be refrigerated at 2 to 8 degrees Celsius before first use. After first use, they can be stored at room temperature (up to 30°C) for up to six weeks. If a product arrives warm with no cold chain packaging, that’s a serious concern.
This isn’t about scaremongering. It’s about the fact that injecting an unregulated substance into your body carries real risks. Stick to registered UK pharmacies.
Frequently Asked Questions
NHS or private — book the GP appointment first.
There are two realistic pathways to Wegovy in the UK in 2026, and neither is instant. The NHS route costs next to nothing but involves a GP referral, strict NICE eligibility criteria, and a potentially lengthy wait for a Tier 3 specialist appointment. The private route is faster but will cost you £2,400 to £3,600 per year. Start by working out your BMI honestly and checking whether you meet the eligibility criteria for either route. Book a GP appointment to discuss a referral, even if you’re considering going private — your GP can flag any medical contraindications and it’s a conversation worth having regardless. Whichever path you choose, use only GPhC-registered pharmacies. The counterfeit market is real, and this is a medication you’re injecting into your body. Check gphc.org.uk, ask questions, and don’t let urgency push you toward an unsafe source.
